// App-Quantinova.ai

: A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Researchers

Presenter

  • Mary Gleeson

Principal Investigators

  • Nicholas Counsell

  • David Cunningham

  • Eliza Hawkes

  • Anthony Lawrie

  • Andrew Jack

  • Paul Smith

  • Christopher Pocock

  • Kirit M. Ardeshna

  • John Radford

  • Andrew McMillan

  • John Davies

  • Deborah Turner

  • Anton Kruger

  • Peter Johnson

  • David C. Linch

Medical Centers

  • GI and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom

  • Cancer Research UK and UCL Cancer Trials Centre/UCL Cancer Institute, London, United Kingdom

  • The Royal Marsden, London & Sutton, United Kingdom

  • Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Australia

  • St James Institute of Oncology, Leeds, United Kingdom

  • East Kent Hospitals, Canterbury, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Kings College London, London, United Kingdom

  • Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Western General Hospital, Edinburgh, United Kingdom

  • Torbay Hospital, Torquay, United Kingdom

  • Royal Cornwall Hospital, Truro, United Kingdom

  • Cancer Research UK Clinical Center, Southampton, United Kingdom

Locations

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Carboxypeptidase E

  • Lactate dehydrogenase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved